<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Bruce Changlong Xu on Bruce C. Xu</title><link>https://brucechanglongxu.github.io/</link><description>Recent content in Bruce Changlong Xu on Bruce C. Xu</description><generator>Hugo</generator><language>en-us</language><managingEditor>you@example.com (Bruce Changlong Xu)</managingEditor><webMaster>you@example.com (Bruce Changlong Xu)</webMaster><lastBuildDate>Thu, 28 Aug 2025 00:00:00 +0000</lastBuildDate><atom:link href="https://brucechanglongxu.github.io/index.xml" rel="self" type="application/rss+xml"/><item><title>Reflections on Organising a Global AI Governance Summit</title><link>https://brucechanglongxu.github.io/posts/hkgagc/</link><pubDate>Thu, 28 Aug 2025 00:00:00 +0000</pubDate><author>you@example.com (Bruce Changlong Xu)</author><guid>https://brucechanglongxu.github.io/posts/hkgagc/</guid><description>&lt;p&gt;Artificial intelligence is advancing faster than the frameworks that might guide its use. Conversations about risk and opportunity are dominated by Washington, Brussels, and Beijing. But if AI is to truly benefit humanity, the conversation cannot remain fragmented — it must be global, inclusive, and grounded in trust. This year, I began organizing the inaugural Hong Kong Global AI Governance Summit alongside one of my closest friends and colleagues. The vision is simple but ambitious: to bring together researchers, policymakers, clinicians, entrepreneurs, and civic leaders from across the U.S., China, and beyond to discuss how we can shape frontier AI toward human flourishing.&lt;/p&gt;</description></item><item><title>Towards Oncological Superintelligence</title><link>https://brucechanglongxu.github.io/posts/towards-oncological-superintelligence/</link><pubDate>Thu, 28 Aug 2025 00:00:00 +0000</pubDate><author>you@example.com (Bruce Changlong Xu)</author><guid>https://brucechanglongxu.github.io/posts/towards-oncological-superintelligence/</guid><description>&lt;p&gt;Cancer has always been a disease of time. Time until the BCR-ABL translocation is recognized in a patient’s marrow; time until sequencing reveals a KRAS mutation in a pancreatic biopsy; time until MYC amplification is confirmed in a lymphoma panel. Time until a therapy is chosen, and then time bought by treatments that stretch survival by months when decades are needed. For patients and families, each interval is both hope and dread. For clinicians, it is the weight of complexity and uncertainty pressed into every decision.&lt;/p&gt;</description></item></channel></rss>